Cargando…

Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia

Antipsychotic medication is the mainstay of treatment in elderly patients with psychosis. In recent years, second generation antipsychotics have come to be preferred. Long-acting risperidone is the first such antipsychotic available for use in this vulnerable group of patients and offers an attracti...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Dhiren, O’Connor, Daniel W
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2739634/
https://www.ncbi.nlm.nih.gov/pubmed/19750235
_version_ 1782171613714710528
author Singh, Dhiren
O’Connor, Daniel W
author_facet Singh, Dhiren
O’Connor, Daniel W
author_sort Singh, Dhiren
collection PubMed
description Antipsychotic medication is the mainstay of treatment in elderly patients with psychosis. In recent years, second generation antipsychotics have come to be preferred. Long-acting risperidone is the first such antipsychotic available for use in this vulnerable group of patients and offers an attractive alternative to traditional medications. The available literature revealed that long-acting risperidone is generally well tolerated and is effective in treating both the positive and negative symptoms of schizophrenia. Despite a lack of randomized trials and head-to-head studies, it appears to be a useful addition to the treatment armory for patients with chronic psychosis who require a depot preparation. Further research into its endocrine and metabolic side effects is needed.
format Text
id pubmed-2739634
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-27396342009-09-10 Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia Singh, Dhiren O’Connor, Daniel W Clin Interv Aging Review Antipsychotic medication is the mainstay of treatment in elderly patients with psychosis. In recent years, second generation antipsychotics have come to be preferred. Long-acting risperidone is the first such antipsychotic available for use in this vulnerable group of patients and offers an attractive alternative to traditional medications. The available literature revealed that long-acting risperidone is generally well tolerated and is effective in treating both the positive and negative symptoms of schizophrenia. Despite a lack of randomized trials and head-to-head studies, it appears to be a useful addition to the treatment armory for patients with chronic psychosis who require a depot preparation. Further research into its endocrine and metabolic side effects is needed. Dove Medical Press 2009 2009-09-01 /pmc/articles/PMC2739634/ /pubmed/19750235 Text en © 2009 Singh and O'Connor, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Singh, Dhiren
O’Connor, Daniel W
Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia
title Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia
title_full Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia
title_fullStr Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia
title_full_unstemmed Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia
title_short Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia
title_sort efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2739634/
https://www.ncbi.nlm.nih.gov/pubmed/19750235
work_keys_str_mv AT singhdhiren efficacyandsafetyofrisperidonelongactinginjectioninelderlypeoplewithschizophrenia
AT oconnordanielw efficacyandsafetyofrisperidonelongactinginjectioninelderlypeoplewithschizophrenia